{"filing":{"accession_number":"0001193125-26-310315","cik":"0001420565","ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-21","report_date":null,"primary_document":"d89210d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312526310315/d89210d8k.htm"},"events":[{"id":19114,"run_id":17202,"accession_number":"0001193125-26-310315","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This Item 5.07 discloses the results of Rein Therapeutics' 2026 Annual Meeting of Stockholders held on July 20, 2026, including voting outcomes on director elections (Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D.), approval of an amendment to increase authorized common shares from 100 million to 200 million, ratification of CBIZ CPAs P.C. as independent auditor, and advisory approval of named executive officer compensation. The filing presents detailed vote tallies for each matter, which is the core disclosure required under Item 5.07 for shareholder meeting results.","company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","filing_date":"2026-07-21","form":"8-K","submitted_at":null,"items":[{"id":18112,"accession_number":"0001193125-26-310315","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of Rein Therapeutics' 2026 Annual Meeting of Stockholders held on July 20, 2026, including voting outcomes on director elections (Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D.), approval of an amendment to increase authorized common shares from 100 million to 200 million, ratification of CBIZ CPAs P.C. as independent auditor, and advisory approval of named executive officer compensation. The filing presents detailed vote tallies for each matter, which is the core disclosure required under Item 5.07 for shareholder meeting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T20:11:46.505012+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18112,"accession_number":"0001193125-26-310315","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of Rein Therapeutics' 2026 Annual Meeting of Stockholders held on July 20, 2026, including voting outcomes on director elections (Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D.), approval of an amendment to increase authorized common shares from 100 million to 200 million, ratification of CBIZ CPAs P.C. as independent auditor, and advisory approval of named executive officer compensation. The filing presents detailed vote tallies for each matter, which is the core disclosure required under Item 5.07 for shareholder meeting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T20:11:46.505012+00:00","company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","filing_date":"2026-07-21"}]}